by 
Cell-based assays are widely used to detect toxicity, efficacy, and potency during drug development and are becoming increasingly important in numerous biological and pharmacological studies. Cell-based assays help monitor the health of cells in normal or experimentally manipulated conditions. They allow real-time, non-invasive monitoring of various cellular responses like cell proliferation, cell viability, signal transduction, etc. Factors such as technological advancements in cell-based assay instruments, growth of the pharmaceutical and biotechnology industries, and increasing R&D expenditure are propelling the global market. The growing stem cell research and neuroscience are also contributing to the market growth.
The global Cell-based Assay Market is estimated to be valued at US$ 1389.5 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Miniaturization of Assays
The demand for miniaturized cell-based assays is increasing owing to less requirement of reagents and samples. Miniaturization offers the benefits of performing multiple assays on the same sample reducing cost and time. Miniaturization technologies like microfluidics help develop assays on a chip with integrated fluid handling control which allows automation, real-time analysis of multiple targets at high-throughput levels. Owing to these benefits, players are focusing on developing miniaturized cell-based assays to improve performance and reduce cost. For instance, Abeyton Diagnostics has developed microfluidic-based immunocapture microsphere assay for detection of biomarkers in small sample volumes.
Porter’s Analysis
Threat of new entrants: The cell-based assay market requires highly technical skills and large capital investments for R&D which acts as a barrier for new entrants.
Bargaining power of buyers: The presence of many established players provides buyers with greater choice and bargaining power.
Bargaining power of suppliers: Due to specialized nature of requirements in cell-based assays, the bargaining power of suppliers remains moderate to high.
Threat of new substitutes: Alternatives like molecular diagnostics pose threat of substitution owing to wider applications.
Competitive rivalry: The market is consolidated with major players fighting for market share through extensive R&D and new product launches.
Key Takeaways
The global cell-based assay market is expected to witness high growth over the forecast period. North America dominates the market currently due to presence of major players and high healthcare spending. High R&D investment and government support is fueling growth in the region.
Europe follows North America in terms of market share in the global cell-based assay market. Rising funding for cell-based research from governments is supporting regional growth. Asia Pacific is expected to witness fastest growth during the forecast period owing to increasing healthcare expenditure, rising initiatives to promote cell-based research.
Key players operating in the cell-based assay market are DiscoverX Corporation, Becton, Dickinson and Company, cell Signaling Technology, Inc., Becton, Danaher Corporation, Thermo Fisher Scientific, Inc., Cisbio Bioassays, Merck & Co., and PerkinElmer, Inc. and others. The market players are involved in new product launches and strategic collaborations to strengthen their market presence.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
